drugset
drugset / Trial / NCT06411730

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

NCT06411730 ↗

Phase 1 Completed 56 enrolled Celgene Corporation
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and drug levels of orally administered BMS-986368 in healthy participants, healthy elderly participants, and healthy participants of japanese ethnicity.

Timeline

Start
2024-05-31
Primary completion
2024-10-28
Completion
2024-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986368 Unknown — Oral

Indications

No indication recorded.